Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, has announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately US$550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Immunovant offered 26.2 million shares of its common stock in the offering at an offering price of US$21 per share. The offering is expected to close on or about December 12, 2025, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriter in the offering with a Capital Markets team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associates Kaj Nielsen, Jie Lin Nai, Kan Ni, and Sean Kim.